Browsing Tag
Exicure
2 posts
Exicure completes Phase 2 trial of GPC-100 for stem cell mobilization in multiple myeloma patients
Exicure (NASDAQ: XCUR) completes final patient visit in Phase 2 GPC-100 trial for stem cell mobilization in multiple myeloma; topline results expected Q4 2025.
Exicure’s stock explodes 78% overnight – but is the comeback for real?
Shares of biopharmaceutical company Exicure Inc. skyrocketed by 78% in after-hours trading, closing at $2.84. The surge came…